Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Medicines for Malaria Venture
Deal Size : $0.2 million
Deal Type : Funding
Mangalam Drugs & Organics Awarded US$ 274,800 Grant by MMV
Details : The grant will support research and development efforts aimed at improving the technology and efficiency of pyronaridine production for pyronaridine-artesunate combination therapy, Pyramax.
Product Name : Pyramax
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 27, 2024
Lead Product(s) : Pyronaridine Tetraphosphate,Artesunate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Medicines for Malaria Venture
Deal Size : $0.2 million
Deal Type : Funding
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Sanaria | University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 01, 2022
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Sanaria | University of Oxford
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyronaridine in Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 22, 2022
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Uganda Cancer Institute | African Center for Cancer Research and End of Life Care (ACREOL), Rwanda | Ifakara Health Institute | Dalal Jamm Hospital, Dakar, Senegal
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Richmond Pharmacology | PharmaKinetic
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 16, 2021
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Richmond Pharmacology | PharmaKinetic
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 24, 2019
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable
Cohort Event Monitoring Study of Pyramax®
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : Pyronaridine Tetraphosphate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Medicines for Malaria Venture
Deal Size : Inapplicable
Deal Type : Inapplicable